Development of a Sensory Entrainment-Integrated Cognitive Game Kit to Improve Cognitive Functions in Alzheimer's Disease
In addition to ongoing drug treatments for Alzheimer Disease (AD), protective approaches that can halt the progression of the disease are of particular importance. This project aims to develop a digital application that can monitor cognitive impairment, using EEG findings proven effective at the clinical level in Alzheimer and various types of dementia, including sensory entrainment and digital cognitive games. To this end, a collaboration between Istanbul Medipol University and Güven Future Health Technologies Inc. will develop a device featuring audio-visual sensory entrainment and digital cognitive games. This device will be made available to Alzheimer patients, and the differences between patients who use the application for three months, patients who do not use the application, and healthy controls will be evaluated through neurological examinations, neuropsychological tests, and EEG recordings indicating cognitive functions by the neurologist, project coordinator, and bursars. Monthly assessments, including EEG recordings, will also continue at home, and an application will be created to evaluate changes in cognitive functions through EEG data. By the end of the project, an application that includes sensory entrainment and digital cognitive games, proven effective at the clinical level using EEG findings for Alzheimer dementia patients, will be developed. Additionally, a health kit capable of temporal monitoring of cognitive function changes through EEG data will have been developed.
• Diagnosed with AD according to DSM-IV and NINCDS-ADRDA criteria,
• Impaired activities of daily living,
• Having a CDR score of 1-2 and an SMMT score of 15-26,
• Stable use of psychoactive medications, including acetylcholinesterase inhibitors or other medications that enhance cognitive functions,
• Individuals aged 60-86 with at least 5 years of education.
• Between the ages of 60-86
• Without any neurological abnormalities or general cognitive impairment (MMSE above 25),
• Not diagnosed with a neurological and/or psychiatric disease,
• Not using neurological and/or psychiatric medication